View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 3, 2021updated 11 Jul 2022 2:19pm

NRx reports positive data from Phase III trial of Covid-19 drug Zyesami

The DSMB advised progressing the subject enrolment to recruit a total of 640 Covid-19 patients in the trial.

NRx Pharmaceuticals has reported that its experimental drug, Zyesami (aviptadil), was found to be safe to treat Covid-19 in the Phase III ACTIV-3b Critical Care clinical trial sponsored by the US National Institutes of Health (NIH).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A synthetic form of a vasoactive intestinal polypeptide, Zyesami attaches to the lung air sac’s alveolar type II cells.

The placebo-controlled, randomised trial is analysing Zyesami and remdesivir (Veklury) as a single agent and in combination versus placebo in hospitalised Covid-19 patients with acute respiratory failure.

These subjects also needed high-flow supplemental oxygen offered by mechanical ventilation, nasal cannula or extracorporeal membrane oxygenation.

The Independent Data Safety Monitoring Board (DSMB) of the trial conducted the third scheduled assessment reviewing more than 300 subjects and detected no novel safety concerns associated with the treatment.

Furthermore, the DSMB recommended advancing the enrolment to recruit a total of 640 subjects in the trial.

NRx Pharmaceuticals chairman and CEO professor Jonathan Javitt said: “This safety analysis by the NIH continues to contribute evidence that Zyesami is safe to administer to patients with critical Covid-19, who have no other therapeutic alternative.

“We now have safety data on nearly 600 patients treated with Zyesami in the ICU or step-down unit, with no reports of unexpected, drug-related, serious adverse events.”

The company had sought emergency use authorization from the US Food and Drug Administration for Zyesami to treat critical Covid-19 patients with respiratory failure, in May 2021.

NRx noted that the application is still pending.

Apart from the ACTIV-3b study, Zyesami is being analysed in two other trials in subjects with severe or critical Covid-19.

In September 2021, NRx reported top-line data from a trial where Zyesami boosted survival outcomes at 12 months in highly comorbid Covid-19 patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena